What to expect when you take Mephyton and Metronidazole?

Do you take Mephyton and Metronidazole? Find out below what new side effects and undetected conditions people who are 50-59 years old may have. This prediction is created after we perform predictive analysis on health care big data. It will be updated regularly.

To personalize this prediction to you, including to your gender, age, personal and family history, and more: Click here



On Aug, 19, 2018

6,180 reports have been studied.


Females aged 50 to 59 :

3,726 related reports were analyzed:

Most common symptoms:

Abdominal pain
  • 7.13% for females aged 50 (±5) who take Metronidazole
Acute kidney failure
  • 5.93% for females aged 50 (±5) who take Mephyton
Anaemia (lack of blood)
  • 6.38% for females aged 50 (±5) who take Metronidazole
Ascites (accumulation of fluid in the abdominal cavity)
  • 7.41% for females aged 50 (±5) who take Mephyton
Bleeding into the skin
  • 5.19% for females aged 50 (±5) who take Mephyton
Depression
  • 5.01% for females aged 50 (±5) who take Metronidazole
Diarrhea
  • 10.11% for females aged 50 (±5) who take Metronidazole
  • 6.67% for females aged 50 (±5) who take Mephyton
Dizziness
  • 6.54% for females aged 50 (±5) who take Metronidazole
Drug hypersensitivity
  • 5.24% for females aged 50 (±5) who take Metronidazole
Dyspnea (difficult or laboured breathing)
  • 6.04% for females aged 50 (±5) who take Metronidazole
Erythema multiforme (a type of hypersensitivity reaction)
  • 8.89% for females aged 50 (±5) who take Mephyton
Fatigue (feeling of tiredness)
  • 6.67% for females aged 50 (±5) who take Mephyton
  • 6.54% for females aged 50 (±5) who take Metronidazole
Fever
  • 11.11% for females aged 50 (±5) who take Mephyton
  • 9.5% for females aged 50 (±5) who take Metronidazole
Haemoglobin decreased
  • 5.19% for females aged 50 (±5) who take Mephyton
Headache (pain in head)
  • 6.6% for females aged 50 (±5) who take Metronidazole
Hepatic failure (liver failure)
  • 10.37% for females aged 50 (±5) who take Mephyton
Hepatic trauma (liver injury)
  • 5.19% for females aged 50 (±5) who take Mephyton
Hepatitis (inflammation of the liver)
  • 5.19% for females aged 50 (±5) who take Mephyton
Hypoaesthesia (reduced sense of touch or sensation)
  • 5.15% for females aged 50 (±5) who take Metronidazole
Hypotension (abnormally low blood pressure)
  • 6.67% for females aged 50 (±5) who take Mephyton
Injury
  • 5.49% for females aged 50 (±5) who take Metronidazole
Joint pain
  • 5.37% for females aged 50 (±5) who take Metronidazole
Lactic acidosis (low ph in body tissues)
  • 5.19% for females aged 50 (±5) who take Mephyton
Metabolic acidosis (body produces too much acid, or when the kidneys are not removing enough acid from the body)
  • 5.19% for females aged 50 (±5) who take Mephyton
Multi-organ failure (multisystem organ failure)
  • 7.41% for females aged 50 (±5) who take Mephyton
Nausea (feeling of having an urge to vomit)
  • 11.06% for females aged 50 (±5) who take Metronidazole
  • 8.89% for females aged 50 (±5) who take Mephyton
Nausea and vomiting
  • 8.24% for females aged 50 (±5) who take Metronidazole
  • 5.19% for females aged 50 (±5) who take Mephyton
Oedema peripheral (superficial swelling)
  • 5.43% for females aged 50 (±5) who take Metronidazole
Osteonecrosis of jaw (death of bone of jaw)
  • 5.82% for females aged 50 (±5) who take Metronidazole
Pain
  • 10.75% for females aged 50 (±5) who take Metronidazole
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
  • 7.41% for females aged 50 (±5) who take Mephyton
Pleural effusion (water on the lungs)
  • 6.67% for females aged 50 (±5) who take Mephyton
Rash erythematous (redness of the skin)
  • 5.19% for females aged 50 (±5) who take Mephyton
Rashes (redness)
  • 6.91% for females aged 50 (±5) who take Metronidazole
Renal failure acute (rapid kidney dysfunction)
  • 5.93% for females aged 50 (±5) who take Mephyton
Respiratory acidosis (respiratory failure or ventilatory failure, causes the ph of blood and other bodily fluids to decrease)
  • 11.11% for females aged 50 (±5) who take Mephyton
Stress and anxiety
  • 9.16% for females aged 50 (±5) who take Metronidazole
Thrombocytopenia (decrease of platelets in blood)
  • 8.89% for females aged 50 (±5) who take Mephyton
Weakness
  • 7.69% for females aged 50 (±5) who take Metronidazole

Most common co-existing conditions:

Depression
  • 5.93% for females aged 50 (±5) who take Mephyton
  • 5.57% for females aged 50 (±5) who take Metronidazole
High blood pressure
  • 9.63% for females aged 50 (±5) who take Mephyton
  • 6.21% for females aged 50 (±5) who take Metronidazole
Nausea (feeling of having an urge to vomit)
  • 6.67% for females aged 50 (±5) who take Mephyton
Pain
  • 11.11% for females aged 50 (±5) who take Mephyton
  • 5.82% for females aged 50 (±5) who take Metronidazole
back to top

Males aged 50 to 59 :

2,454 related reports were analyzed:

Most common symptoms:

Acute kidney failure
  • 10.45% for males aged 50 (±5) who take Mephyton
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection)
  • 7.27% for males aged 50 (±5) who take Mephyton
Anaemia (lack of blood)
  • 7.27% for males aged 50 (±5) who take Mephyton
Arrhythmias (irregular heartbeat)
  • 5.45% for males aged 50 (±5) who take Mephyton
Blood creatinine increased
  • 5.45% for males aged 50 (±5) who take Mephyton
Chest pain
  • 10.91% for males aged 50 (±5) who take Mephyton
Chills (felling of cold)
  • 5.0% for males aged 50 (±5) who take Mephyton
Cholestasis (a condition where bile cannot flow from the liver to the duodenum)
  • 5.45% for males aged 50 (±5) who take Mephyton
Dehydration (dryness resulting from the removal of water)
  • 10.0% for males aged 50 (±5) who take Mephyton
Depression
  • 5.91% for males aged 50 (±5) who take Mephyton
Diarrhea
  • 6.62% for males aged 50 (±5) who take Metronidazole
  • 5.45% for males aged 50 (±5) who take Mephyton
Drug ineffective
  • 5.45% for males aged 50 (±5) who take Mephyton
Dyspnea (difficult or laboured breathing)
  • 10.45% for males aged 50 (±5) who take Mephyton
Erythema multiforme (a type of hypersensitivity reaction)
  • 7.73% for males aged 50 (±5) who take Mephyton
Fatigue (feeling of tiredness)
  • 5.91% for males aged 50 (±5) who take Mephyton
  • 5.64% for males aged 50 (±5) who take Metronidazole
Fever
  • 10.45% for males aged 50 (±5) who take Mephyton
  • 8.28% for males aged 50 (±5) who take Metronidazole
Hepatic failure (liver failure)
  • 5.45% for males aged 50 (±5) who take Mephyton
Hypotension (abnormally low blood pressure)
  • 9.09% for males aged 50 (±5) who take Mephyton
  • 5.1% for males aged 50 (±5) who take Metronidazole
International normalised ratio increased
  • 9.55% for males aged 50 (±5) who take Mephyton
Multi-organ failure (multisystem organ failure)
  • 7.27% for males aged 50 (±5) who take Mephyton
Nausea (feeling of having an urge to vomit)
  • 7.73% for males aged 50 (±5) who take Mephyton
Nausea and vomiting
  • 5.91% for males aged 50 (±5) who take Mephyton
Oedema peripheral (superficial swelling)
  • 8.18% for males aged 50 (±5) who take Mephyton
Pleural effusion (water on the lungs)
  • 5.91% for males aged 50 (±5) who take Mephyton
Pneumonia
  • 6.36% for males aged 50 (±5) who take Mephyton
Rashes (redness)
  • 5.42% for males aged 50 (±5) who take Metronidazole
Renal failure acute (rapid kidney dysfunction)
  • 11.82% for males aged 50 (±5) who take Mephyton
Sepsis (a severe blood infection that can lead to organ failure and death)
  • 6.82% for males aged 50 (±5) who take Mephyton
Septic shock (shock due to blood infection)
  • 6.36% for males aged 50 (±5) who take Mephyton
Stress and anxiety
  • 5.91% for males aged 50 (±5) who take Mephyton
Thrombocytopenia (decrease of platelets in blood)
  • 10.45% for males aged 50 (±5) who take Mephyton
Weight decreased
  • 5.91% for males aged 50 (±5) who take Mephyton

Most common co-existing conditions:

Crohn's disease (condition that causes inflammation of the gastrointestinal tract)
  • 5.95% for males aged 50 (±5) who take Metronidazole
Multiple myeloma (cancer of the plasma cells)
  • 9.09% for males aged 50 (±5) who take Mephyton
Pain
  • 6.36% for males aged 50 (±5) who take Mephyton
  • 5.15% for males aged 50 (±5) who take Metronidazole
back to top

Related studies

Mephyton

Mephyton has active ingredients of phytonadione. (latest outcomes from Mephyton 512 users)

Metronidazole

Metronidazole has active ingredients of metronidazole. It is often used in vaginitis bacterial. (latest outcomes from Metronidazole 23,757 users)

Mephyton and Metronidazole

Related publications that referenced our studies


Analysis tools (to study 499 million drug outcomes from FDA)

  • Check symptoms - identify the cause of a symptom: from a drug or from a condition?
  • Check drugs - find out common side effects or drug interactions of my drugs.
  • Compare drugs - compare the side effects and efficacy of multiple drugs side by side.

You are not alone. Join our personalized support groups:

You may be interested in these posts

More posts for: Mephyton, Metronidazole

Recent updates

General studies
Active Support Groups
Recent Care Guides

No recent care guides.


WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on ePatient.care is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the ePatient.care site and its content is at your own risk.